{"filing":{"accession_number":"0001437749-26-026256","cik":"0001625101","ticker":"PLSE","company_name":"PULSE BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"plse20260518_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926026256/plse20260518_8k.htm"},"events":[{"id":25743,"run_id":23363,"accession_number":"0001437749-26-026256","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses quarterly financial results for Q2 2026 (ended June 30, 2026) through a press release attached as Exhibit 99.1. The Item 2.02 section explicitly states \"the Company announced certain financial and operational results for the fiscal quarter ended June 30, 2026,\" and the press release presents revenue ($0.4M), GAAP net loss ($24.7M), non-GAAP net loss ($19.4M), cash position ($101.6M), and operating cash burn ($18.7M), along with business updates on clinical trials and product development. This is a standard quarterly earnings announcement.","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26652,"accession_number":"0001437749-26-026256","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses quarterly financial results for Q2 2026 (ended June 30, 2026) through a press release attached as Exhibit 99.1. The Item 2.02 section explicitly states \"the Company announced certain financial and operational results for the fiscal quarter ended June 30, 2026,\" and the press release presents revenue ($0.4M), GAAP net loss ($24.7M), non-GAAP net loss ($19.4M), cash position ($101.6M), and operating cash burn ($18.7M), along with business updates on clinical trials and product development. This is a standard quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:30:29.116835+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26652,"accession_number":"0001437749-26-026256","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses quarterly financial results for Q2 2026 (ended June 30, 2026) through a press release attached as Exhibit 99.1. The Item 2.02 section explicitly states \"the Company announced certain financial and operational results for the fiscal quarter ended June 30, 2026,\" and the press release presents revenue ($0.4M), GAAP net loss ($24.7M), non-GAAP net loss ($19.4M), cash position ($101.6M), and operating cash burn ($18.7M), along with business updates on clinical trials and product development. This is a standard quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:30:29.116835+00:00","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-08-06"}]}